Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

Ravinder N. Maini(Imperial College London), E. William St. Clair(Duke University), Ferdinand C. Breedveld(Leiden University), Daniel E. Fürst(Virginia Mason Medical Center), Joachim R. Kalden, Michael H. Weisman(University of California, San Diego), Josef S. Smolen(University of Vienna), Paul Emery(University of Leeds), Gregory R. Harriman, Marc Feldmann(Charing Cross Hospital), Peter E. Lipsky(The University of Texas Southwestern Medical Center)
The Lancet
December 1, 1999
Cited by 2,355

Abstract


Related Papers

No related papers found

Powered by citation graph analysis